Pipeline
Development status (JP)
Please scroll horizontally to check
| Development stage | Code name,generic name | Indication | Origin | Development | Remarks |
|---|---|---|---|---|---|
| Phase III | TA799, apraglutide |
Short bowel syndrome | Licensed: Ironwood Pharmaceuticals, Inc. | Ironwood Pharmaceuticals, Inc. | Phase I in Japan was conducted by Asahi Kasei Pharma |
| Phase II | ART-123, recombinant thrombomodulin alfa |
Chemotherapy- induced peripheral neuropathy (CIPN) | In-house | Asahi Kasei Pharma Corporation and Veloxis Pharmaceuticals | Additional indication Joint U.S.-Japan Phase I study in progress |
| Phase II | AK1830 | Pain associated with osteoarthritis Chronic low back pain | Licensed：Array BioPharma Inc., a wholly owned subsidiary of Pfizer, Inc. | Asahi Kasei Pharma Corporation | |
| Phase I | AK1910 | Autoimmune diseases | Licensed：SBI Biotech Co., Ltd. | Asahi Kasei Pharma Corporation |
Development status (Global)
Please scroll horizontally to check
| Development stage | Code name,generic name | Indication | Origin | Development | Region |
|---|---|---|---|---|---|
| Phase III | ART-123, recombinant thrombomodulin alfa |
Severe sepsis with coagulopathy | In-house | Asahi Kasei Pharma Corporation | United States, Europe, etc. |
| Phase I | ART-123, recombinant thrombomodulin alfa |
Chemotherapy- induced peripheral neuropathy (CIPN) | In-house | Asahi Kasei Pharma Corporation and Veloxis Pharmaceuticals | United States |
Development status (licensed out)
Please scroll horizontally to check
| Development stage | Code name,generic name | Indication | Origin | Development | Region |
|---|---|---|---|---|---|
| Phase II | LY3857210 | Chronic Pain | In-house (co-research with RaQualia Pharma Inc.) | Eli Lilly and Company | Global (AKP has rights to promote LY3857210 in Japan and China) |